|

Radotinib HCl Clinical Trials

1 actively recruiting trial

Also known as: SUPECT

Pipeline

Phase 3: 1

Top Sponsors

  • Il-Yang Pharm. Co., Ltd.1

Indications

  • CML - Philadelphia Chromosome1
  • CML, Refractory1
  • CML, Chronic Phase1
  • Chronic Myeloid Leukemia, Chronic Phase1
  • Cancer1

Other1 trial

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.